Integrative gut microbiota and metabolomics reveals the mechanism of chicory extract in improving metabolic dysfunction-associated steatotic liver disease via gut-liver axis
Phytomedicine · 2025-11 · 148 · 157404
DOI: 10.1016/j.phymed.2025.157404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2025-11. Verfasst von Haifeng Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Basic Medical Sciences, Hubei Shizhen Laboratory, Key Laboratory of Chinese Medicinal Resource and Chinese Herbal Compound of the Ministry…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Plant Extracts, Cichorium intybus, Fatty Liver. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Chicory (Cichorium intybus l.) has shown an efficacy anti-metabolic dysfunction-associated steatotic liver disease (MASLD) in basic research and clinical applications, but its pharmacodynamic mechanism remains unclear. PURPOSE: This work aims to clarify the pharmacological mechanism of chicory aqueous extract (CE) in improving MASLD from the perspective of gut-liver interaction. METHODS: MASLD mice induced by a high-fat diet were employed as the in vivo model, while palmitic acid-induced AML12 cells served as the in vitro model. Combined qRT-PCR and Western blot to detect the expression of lipid metabolism-related genes/proteins. 16S rDNA sequencing and gut microbiota depletion experiments were conducted to elucidate the CE-gut microbiota interaction. UPLC-Q-TOF-MS was employed to analyze the chemical components of CE and plasma metabolite profiles. RESULTS: CE significantly inhibited body weight gain, improved hepatic lipid deposition, and down-regulated the expression of SREBP1 and SCD1 in MASLD mice. 16S rDNA sequencing and antibiotic-depleted microbiota experiments showed that CE significantly affected the diversity and community richness of gut microbiota, and its efficacy depended on the presence of gut microbiota. Metabolomics identified plasma taurodeoxycholic acid (TDCA) as a core metabolite of CE intervention, and its level was positively correlated with the abundance of microbial bile salt hydrolase (BSH). Furthermore, in vitro experiments confirmed that TDCA dose-dependently inhibited lipid accumulation in AML12 hyperlipidemic cells. CONCLUSIONS: CE exerts an anti-MASLD effect by remodeling the gut microbiota to promote TDCA synthesis, thereby suppressing SREBP1/SCD1 axis. This provides a theoretical foundation for developing gut-liver axis-targeted natural therapies against MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Basic Medical Sciences, Hubei Shizhen Laboratory, Key Laboratory of Chinese Medicinal Resource and Chinese Herbal Compound of the Ministry of Education, Hubei University of Chinese Medicine, Wuhan 430065, Chi…
- Wuhan Center for Clinical Laboratory, Wuhan 430015, China.
Zitieren
APA
Wang, H., Liu, S., Chen, Y., Fang, W., Cheng, Y., Zhang, Z., Hu, H., Hu, B., & Liu, H. (2025). Integrative gut microbiota and metabolomics reveals the mechanism of chicory extract in improving metabolic dysfunction-associated steatotic liver disease via gut-liver axis. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157404
Vancouver
Wang H, Liu S, Chen Y, Fang W, Cheng Y, Zhang Z, et al. Integrative gut microbiota and metabolomics reveals the mechanism of chicory extract in improving metabolic dysfunction-associated steatotic liver disease via gut-liver axis. Phytomedicine. 2025. doi:10.1016/j.phymed.2025.157404
BibTeX
@article{Wang2025,
author = {Wang, Haifeng and Liu, Songlin and Chen, Yonggang and Fang, Weiwei and Cheng, Ying and Zhang, Zhigang and Hu, Haiming and Hu, Baifei and Liu, Hongtao},
title = {Integrative gut microbiota and metabolomics reveals the mechanism of chicory extract in improving metabolic dysfunction-associated steatotic liver disease via gut-liver axis},
journal = {Phytomedicine},
year = {2025},
doi = {10.1016/j.phymed.2025.157404}
}
EUVIMED